Developmental Biology Program

The Mary Baylies Lab

Research

Mary Baylies, PhD
Mary Baylies, PhD


Professor

Developmental biologist Mary Baylies studies the mechanisms that form and maintain muscle both during normal development and in disease.

 

View Lab Overview

Research Projects

The Baylies Lab

Publications

Windner SE, Manhart A, Brown A, Mogilner A, Baylies MK. (2019.) Nuclear Scaling Is Coordinated among Individual Nuclei in Multinucleated Muscle Fibers. Dev Cell. Apr 8;49(1):48-62.e3. Featured as a cover image and in a Preview.

View All Publications

People

Mary Baylies, PhD

Mary Baylies, PhD



Professor

  • Developmental biologist Mary Baylies studies the mechanisms that form and maintain muscle both during normal development and in disease.
  • PhD, The Rockefeller University
[email protected]
Email Address
212-639-5888
Office Phone
Download CV
PDF File

Members

Mary Baylies, PhD
Mary Baylies

Member

David Soffar
David Soffar

Research Technician

Bianca Borchin
Bianca Borchin

Research Fellow

Patrick Busch, Graduate Student
Patrick Busch

Graduate Student

Briana Christophers
Briana Christophers

Graduate Student

Meg Distini
Meg Distini

Administrative Assistant

Therade Jashari
Therandë Jashari

Graduate Student

Ruth Silimon
Ruth Silimon

Graduate Student

Nicole J. Torres-Santiago
Nicole J. Torres-Santiago

MSK Bridge Program Scholar

Victoria von Saucken
Victoria von Saucken

Graduate Student

Stefanie Windner
Stefanie Windner

Research Fellow

Carol Zapater i Morales
Carol Zapater i Morales

Graduate Student

Lab Alumni
Lab Affiliations

Achievements

  • Identified that global, regional, and local inputs contribute to nuclear size regulation in multinucleated skeletal muscle fibers.
  • Demonstrated that properly placed nuclei are critical for healthy muscle function.
  • Discovered that microtubules are critical for the movement and positioning of nuclei in the multinucleated skeletal muscle cell.
  • Developed Drosophila models of muscle wasting in cancer cachexia and aging.
  • Identified how actin filament dysregulation contributes to skeletal muscle dysfunction in models of nemaline myopathy.
Read more
  • Developed a Drosophila model for metastasis in alveolar rhabdomyosarcoma, a type of soft tissue cancer most often seen in children.
  • Described how nuclear polarization occurs during myonuclear movement in vivo.
  • Completed the first spatial and temporal characterization of an F-actin structure that forms at the myoblast fusion site.
  • Identified transcription factors and chromatin regulators that are critical for muscle identity.
  • Identified 3-D arrangement of myoblasts that occur during muscle specification and morphogenesis.
  • Discovered signal transduction pathways (Notch, Wnt, BMP, and RTK) and transcription factors that are critical for muscle identity.
  • President of the Society for Muscle Development (2009-2013).
  • Frederick Adler Chair for Junior Faculty (1997-2003).

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Mary Baylies discloses the following relationships and financial interests:

  • French National Research Agency
    Provision of Services (uncompensated)
  • Howard Hughes Medical Institute
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures